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Multiple myeloma is the second most common haematological cancer. It affects quality of life 
(QOL) due to physical symptoms and psychosocial impairments. Routine assessment of QOL 





To develop and validate an instrument to assess the QOL of people with multiple myeloma 




The Myeloma Patient Outcome Scale (MyPOS) was developed in a multi-phased study 
including qualitative interviews, cognitive interviews, and a cross sectional survey. 
 
Phase 1: Semi-structured qualitative interviews explored the meaning of QOL and views on 
existing QOL questionnaires from the patients’ perspective.  Focus groups of patients and 
healthcare professionals further explored the meaning of QOL and desired utility of QOL 
questionnaires in clinical practice. Purposive sampling used throughout except patient focus 
groups due to feasibility. Thematic analysis identified emergent themes and used to develop 
a theoretical model of QOL in myeloma. 
 
Phase 2: Above findings used to develop a prototype MyPOS. Cognitive interviews used to 
evaluate and refine the MyPOS in a purposive sample of myeloma patients. 
 
Phase 3: A national multi-centre survey of myeloma patients to evaluate the psychometric 
properties of the MyPOS, recruiting from 14 hospital trusts across England. A clinically 







Phase I:  57 participants were recruited across the semi-structured interviews and focus 
groups.  Emergent themes important to QOL were: Biological Status, Treatment Factors, 
Symptom Status, Activity and Participation, Emotional Status, Support, Expectations, 
Adaptation and Coping and Spirituality.  Most fundamental to QOL were Activity and 
Participation, Emotional Status and Support.   Symptoms had an indirect effect on QOL, only 
affecting QOL if they impacted more fundamental domains.  Health service factors were 
particularly important, and sexual dysfunction was highlighted by patients and healthcare 
professionals as a difficult issue to raise in a typical clinical encounter. 
 
Phase 2: The MyPOS was developed as an adaptation of the existing POS questionnaire, 
taking account of the above findings.  Cognitive interviews with 12 participants resulted in 
refinement of the 33-item preliminary MyPOS to a 30-item tool for field testing. 
 
Phase 3: 380 participants took part in the cross sectional survey.  The mean time to complete 
was 7 minutes 19 seconds with 0.58% missing MyPOS items overall.  Internal consistency was 
high (α=0.89).  Principle component analysis suggested three subscales in line with the 
theoretical model of QOL: Symptoms and Function; Emotional Response; and Healthcare 
Support. Total MyPOS scores were higher (worse QOL) in those with relapsed or progressive 
disease compared to newly diagnosed or stable disease (F=II.89, p<0.00I) and were worse in 
those currently receiving chemotherapy (t=3.42, p<0.001). Scores in the Symptoms and 
Function subscale were higher (worse QOL) in those with worse ECOG performance status 
(F=31.33, p<0.001).  Good convergent and divergent validity were demonstrated against 




The MyPOS is the first QOL tool designed specifically for use within the clinical care of 
myeloma patients.  It has a theoretical foundation, is acceptable to patients, with good 
internal consistency, structural validity and construct validity. Further work is needed to 
evaluate test-re-test reliability, responsiveness to change and minimal important difference, 
alongside testing of MyPOS’s ability to facilitate a more successful clinical encounter. 
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1.   Background 
 
1.1.   Introduction 
 
Multiple myeloma is a malignant neoplasm of bone marrow plasma cells characterised by 
destruction of the bones, anaemia, renal failure and hypercalcaemia (raised blood calcium).  
It represents 1% of all cancer in the UK and is the second most common haematological 
cancer (1).  Recent years have seen an expansion of available treatment options for myeloma 
patients, with survival improving from months to years in some cases (2).  However, a cure 
has remained elusive and alongside improved survival has emerged a greater interest in the 
impact of disease and treatment on quality of life (QOL). 
 
Myeloma causes an array of physical symptoms including pain, fatigue and bleeding (3).  
Disease related symptoms are compounded by the side effects and complications of 
treatment such as gastrointestinal disturbance, painful mucositis and peripheral neuropathy, 
as well changes in body image and impaired psychosocial and sexual function.  Several 
researchers have demonstrated impaired QOL (4-6) and unmet supportive care needs (7) in 
people diagnosed with myeloma.  There is also evidence that myeloma patients suffer more 
problems and worse overall QOL than those with other haematological cancers (8).  This has 
led some to suggest that QOL screening should be routine in the clinical care of myeloma 
patients (4, 5, 9), or may help with prognostication (10, 11). However, there are currently no 
myeloma-specific QOL tools designed specifically for use in the clinical setting.  
 
This study seeks to improve the routine assessment of QOL of myeloma patients by 
developing a QOL tool that is suitable for routine clinical use.  The tool will be centred on the 
concerns and needs of patients and be designed with clinical applications in mind. 
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1.2.   Multiple myeloma 
 
1.2.1.   Epidemiology 
 
Multiple myeloma affects about 0.4 to 5 per 100,000 people per year globally, with a higher 
incidence in developed countries and an increasing incidence worldwide (12).  In the UK 
myeloma accounts for 2% of all new cases of cancer, and the age standardised incidence was 
8.7 per 100,000 people in 2012 (1).  It is predominantly a disease of older people with a 
median age at diagnosis of around 73 years (13).  Figure 1 shows increasing incidence with 
age and higher incidence in men than women.  This translates into a male to female ratio of 
1.4:1 (14).  Figure 2 shows an increase in UK incidence over time (1), which is almost certainly 
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Figure 2:   Trends in age standardised incidence of multiple myeloma per 100,000 people, by gender, UK (1) 
 
 
1.2.2.   Evolving treatment, improved survival 
 
Left untreated the median survival of people with myeloma is less than 12 months (2).   With 
the introduction of alkylating agents such as melphalan and glucocorticoids in the 1960’s this 
was increased to beyond 30 months (15, 16).  This remained the mainstay of treatment for 
about 30 years, until the 1990’s when overall survival (OS) times in excess of 43 months were 
demonstrated with high dose chemotherapy (HDT) and bone marrow transplant (BMT) in 
both refractory disease (17) and newly diagnosed patients (18).  Bone marrow transplant has 
now been replaced by peripheral blood stem cell (PBSC) support and this remains standard 
consolidation therapy in newly diagnosed patients to this day.  Median survival is now over 
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Those receiving HDT and PBSC suffer with severe gastrointestinal disturbance, pain and 
fatigue (4-6). The toxicity of this treatment means that it must generally be reserved for those 
younger than 65 (19).  Melphalan remains the mainstay of HDT and is associated with 
increased risk of bone marrow toxicity, reduced stem cell production, associated 
immunodeficiency, and secondary problems such as myelodysplasia (20). These conditions 
lead to symptoms and problems such as bleeding, fatigue and an impaired immune system, 
which all can have an impact on QOL.  Over the years newer classes of so-call ‘novel’ drugs 
have been incorporated into the treatment of myeloma. These are drugs such as thalidomide, 
lenalidamide (Revlimid) and bortezomib (Velcade).  These have greatly expanded treatment 
options, especially for those not able to tolerate HDT, and can be used alone or in 
combination with conventional therapies (19, 21, 22). These novel agents have only reached 
clinical practice in recent years, and allow the exploration of therapy that is less toxic, and 
sometimes more effective than in the past.   However, alongside these new treatments have 
emerged new side effects and toxicities such as peripheral neuropathy, which causes tingling 
and numbness in the hands and/or feet that can persist for years after the treatment is given 
(23), and cause significant impairments in QOL (24). 
 
1.3.   Quality of life 
 
The impact of myeloma on the lives of those affected extends beyond just the physical 
symptoms and complications.  Myeloma has also been shown to affect emotional wellbeing 
as well as cognitive, social and role functioning (4-7, 9).  Considering and optimising all of 
these QOL domains is therefore important to the good clinical care of myeloma patients. 
 
Over the past 30 years there has been a growing interest in QOL within healthcare and its 
related disciplines.  Clinicians and policy makers increasingly recognise the importance of 
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understanding and assessing QOL, and this has led to an overcrowded marketplace of 
literature for those who seek an appropriate tool or model for use in a given context or 
patient group.  This chapter aims to summarise some of the challenges faced when trying to 
define and assess QOL.   The literature summarised here is confined to that which has 
relevance to healthcare, with an emphasis on oncology and haematology where possible. 
 
1.3.1.   What is quality of life? 
 
There remains no consensus definition for QOL.  Healthcare professionals, researchers, 
economists and lay people all use the term, and its exact meaning varies depending on the 
context in which it is used.  Farquhar reports a detailed taxonomy of meanings for QOL and 
suggests that the lack of a consensus definition is directly rooted in its multidisciplinary use   
(25).  In attempting to define QOL, Bowling notes that ‘quality’ is a grade of goodness and so 
quality of life refers to the goodness of life (26).  This purely linguistic interpretation presents 
QOL as a ‘positive state’ related only to goodness.  However, healthcare and policy research 
regard QOL more as a ‘state’, which can exist anywhere along a spectrum from good to bad. 
 
Within healthcare research the term QOL is often operationally defined by the tools used to 
assess it (“we measured QOL using the EQ-5D questionnaire”).  However, others use the term 
to describe a more latent concept that can only be approximated by a questionnaire (“we 
evaluated the EQ-5D questionnaire in terms of its ability to capture QOL”).   In the first of the 
these examples, the speaker is assuming not that EQ-5D is good at measuring QOL, but that 
the EQ-5D is quality of life for the purposes of their study.  These subtle but important 
differences in the use of the term makes it difficult to interpret or directly compare findings 
across studies (25). 
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1.3.2.   What is ‘health-related’ quality of life? 
 
Health related quality of life (HRQOL) is regarded as one component of overall QOL (26).  On 
a semantic level, this definition ‘ring fences’ those aspects of QOL affected by health, and 
defines them as HRQOL – thereby allowing separate assessment of ‘health related’ and ‘non-
health related’ components.  Leplege comments that this view fails to recognise the 
interconnectedness of health status with wider aspects of life – such as work life and leisure 
pursuits (27).  Similarly, others have also argued that as an individual becomes more unwell, 
almost all areas of life can become health related (28).  This casts doubt on the plausibility of 
assessing HRQOL separately from overall QOL . 
 
Another way of exploring a definition for HRQOL is to examine the definition of health itself.  
In its 1946 constitution The World Health Organisation defined health as “a state of complete 
physical, mental and social wellbeing, and not merely the absence of disease or infirmity” 
(29).   This definition has not changed since it was written, and has been widely adopted 
since.   It would seem to cast further doubt on the likelihood of assessing HRQOL as distinct 
from QOL.   By defining health as broader than just disease or infirmity, the scope of HRQOL 
grows beyond the absence of disease and into a state of complete physical, mental and social 
wellbeing. 
 
However, when moving into clinical practice it would seem clear that there are things other 
than health that can determine QOL, even for the sickest of patients.  For example, two 
people with myeloma both report reduced QOL because they are unable to go shopping – 
one is rendered immobile by pain (health-related); the other is prevented by a lack of public 
transport (non-health related).  Similarly, people with the same health state can report very 
different HRQOL because of differences in their personal beliefs or circumstances.  For 
example, two people with myeloma are admitted to hospital for chemotherapy – one reports 
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a large impact on HRQOL due to financial and childcare concerns; the other is retired with 
fewer time commitments and so reports less impact on HRQOL.  HRQOL is therefore 
determined not only by biological factors and health states, but also by individual perceptions 
and circumstances. 
 
Much like QOL, a variety of definitions for HRQOL are found throughout the literature, which 
vary in their scope.  Ferrans suggests that definitions of HRQOL can be divided into three 
categories based on their scope, ranging from the most narrow to the most broad (30).  
These three categories are reproduced below in Table 1, with examples from the literature. 
   
Table 1:   Scope of HRQOL: Categories of definitions, reproduced from (30) 
1) Quality of life within the purview of healthcare 
Schipper 1996 (31) QOL in clinical medicine represents the functional effect of an illness and its consequent 
therapy upon a patient, as perceived by the patient. 
2) Impact of illness on quality of life 
Cella 1995 (32) HRQOL refers to the extent to which one’s usual or expected physical, emotional, and 
social wellbeing are affected by a medical condition or its treatment. 
Ebrahim 1995 (33) HRQOL may be thought of as those aspects of self-perceived well-being that are related to 
or affected by the presence of disease or treatment. 
Revicki 2000 (34) HRQOL is defined as the subjective assessment of the impact of disease and its treatment 
across physical, psychological, social and somatic domains of functioning and well-being. 
3) Quality of life during illness 
Osoba 1994 (35) HRQOL is a multidimensional construct encompassing perceptions of both positive and 
negative aspects of dimensions, such as physical, emotional, social, and cognitive functions, 
as well as the negative aspects of somatic discomfort and other symptoms produced by 
disease or its treatment. 
Padilla 1996 (36) HRQOL is defined as a personal, evaluative statement summarising the positivity or 
negativity of attributes that characterize one’s physical, psychological, social and spiritual 
well-being at a point in time when health, illness and treatment conditions are relevant 
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The first category sees HRQOL purely within the purview of healthcare.  This is the narrowest 
type of definition, with a primary focus on the negative consequences of illness that might be 
amenable to intervention by healthcare providers (such as pain or immobility).  This type of 
definition perhaps best services the needs of the typical healthcare provider, who may be 
most concerned with identifying problems that they are able to fix.  The example given in 
Table 1 by Schipper focuses entirely on the functional consequences of disease or treatment. 
 
The second category in Table 1 takes a wider view, encompassing all areas of interest to 
healthcare professionals and also other areas of life such as the impact of disease on social or 
spiritual well-being.  Many healthcare providers would be less interested in these domains, 
since they are less tangible and more difficult to fix within the restraints of a given service.  
However, it may be important to identify them in settings such as the treatment and 
palliation of incurable cancers such as myeloma, in which a greater emphasis on holistic care 
may be required.  Although these definitions take a more holistic view, they are still restricted 
to the impact of disease on quality of life – they pose the question “how has illness affected 
QOL?” – and so they maintain a general focus on negative effects. 
 
The third category is the broadest, and simply asks “what is important to quality of life?”  This 
widens the scope to include both positive and negative issues, and fits better with the notion 
that disease can affect all aspects of life.  
 
The chosen definition of QOL or HRQOL should suit the context in which it is used.  For 
example, in a trial designed to evaluate the adverse effects of a drug, a more narrow 
definition may be appropriate since the focus is to identify physical side effects of the 
treatment.  However, when designing a QOL questionnaire for use in the clinical care of 
myeloma patients, a wider definition would be more appropriate – since an understanding of 
the whole person and their wider experience are all important to good holistic care.  
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Some areas of consensus do exist in definition of QOL.  Most authors concur that QOL is some 
property of an individual that is: (i) subjective and dependant on individuals’ perceptions; (ii) 
multidimensional, involving at least physical, psychological and social components, and (iii) 
dynamic over time (27, 37, 38). 
 
For the purposes of the present study the term QOL will be used, rather than HRQOL.  This is 
to reflect the fact that in clinical practice all elements of QOL should be relevant to those 
aiming to deliver good holistic care.  This view was reached after data collection had been 
completed.  Therefore the term HRQOL is used throughout Publication 1, which was written 
and published as background literature review prior to data collection being completed. 
 
1.3.3.   ‘Measurement’ or ‘Assessment’ of QOL? 
 
The act of collecting QOL data using questionnaires is described throughout the literature in 
different ways, including ‘measurement’, ‘assessment‘ or ‘estimation’ of QOL.  Authors often 
pay little attention to the precise meaning of these terms.  It is important to consider that the 
QOL data obtained from questionnaires are usually ordinal, and some would argue that the 
collection of such data cannot be described as ‘measurement’, since only continuous 
variables can truly be measured.  
 
The definition of measurement has a long and complex history, and remains a subject of 
debate to the present day.  Many different definitions exist, with varying degrees of overlap 
and disagreement.  The debate which is perhaps most relevant to the field of QOL research 
exists broadly between the social sciences and physical sciences.  Perhaps the most widely 
used definition of measurement used in psychology was proposed by Stevens in 1946 as “the 
assignment of numerals to objects or events according to rules” (39).   This sees measurement 
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as any process of ascribing numbers to a phenomenon, as long as the numbers are applied 
according to a set of rules or conventions.  This permissive definition is popular with 
psychologists because it encompasses the collection of ordinal data (such as QOL) about 
human sensations, experiences and perceptions. 
 
However, Stevens’ definition has been criticised by those within the physical sciences, who 
see measurement as something that must occur along a continuous and additive scale.  An 
alternative definition which recognises this was proposed by Michell in 1997 as “the 
numerical estimation of the ratio of a magnitude of a quantitative attribute to a unit of the 
same attribute” (40).   Adopting this definition would exclude the collection of ordinal or 
categorical data (such as in QOL). 
 
This debate is really about semantics.  The social and physical sciences are both clear about 
their scientific activities – but each side is trying to use the term ‘measurement’ to describe 
what they do.   Whichever definition is adopted, measurement can be seen as a specific type 
or component of assessment.   Assessment is an umbrella term, encompassing measurement 
and any other attempt to describe a phenomenon.  This makes assessment a more suitable 
term in the field of QOL research.   This is particularly the case since QOL tools do not always 
seek to quantify the phenomenon of interest, but may be used in clinical settings to identify 
and prioritise problems, or facilitate communication (41).  As such, the term assessment is 
adopted henceforth throughout this thesis.  
 
1.3.4.   Challenges in the assessment of quality of life 
 
QOL cannot be directly observed – it is a latent concept (or latent variable) the existence of 
which is inferred.   Assessment of QOL relies on asking respondents questions about related 
issues (such as pain, physical function, distress) and using these as indicators of underlying 
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QOL.   The link between these related issues and QOL should be based on a theory or model 
of QOL, although this is not always the case in the literature (37).  A QOL instrument should 
also be valid, reliable, responsive to change, acceptable to respondents and interpretable by 
professionals (37, 42-44).   More specific considerations in developing QOL tools are rooted in 
the three consensus properties of QOL identified earlier: 
 
1. QOL is subjective.  QOL instruments should be centred on the concerns of the 
respondent.  This poses a challenge for the use of structured tools with pre-defined 
questions, and has led some to propose the inclusion of open ended questions such as 
“Is there anything else important that has affected your quality of life?” (45, 46), or 
even that all QOL domains in the tool should be nominated by the respondent (47). 
 
2. QOL is multidimensional.   Traditional psychometric scales frequently measure 
concepts such as mathematical ability that are considered unidimensional.  There is 
growing evidence and consensus that QOL is multidimensional, incorporating physical, 
psychological and social domains (26, 27, 38, 48).   It is important to draw this 
distinction during development of a tool because some mathematical models used in 
the development process assume unidimensionality of the latent variable (e.g. some 
item response theory methods) (49). 
 
3. QOL is dynamic.    QOL can be affected by biological, environmental or individual 
factors, any of which can change over time.  Myeloma may enter remission following 
treatment (change in biological factors); employment status may change 
(environmental factors); or people may undergo a shift in their internal standards 
through adaptation to illness (so called ‘response-shift’ (50)). 
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1.3.5.   Assessment of QOL in clinical practice 
 
QOL assessment tools are used in many different contexts – including research, economic 
evaluations, and clinical practice.   Within clinical practice QOL assessments can be brought to 
bear through two main mechanisms.  Firstly, the data obtained in research can be used to 
guide subsequent treatment recommendations or change practice (51, 52).  Secondly, QOL 
tools may be used as an integrated part of routine clinical care (41, 53).  It is the latter of 
these two applications that is of primary interest in the current study. 
 
Routine QOL life assessments alongside clinical care may help guide practice in a number of 
ways.  Several authors have outlined the potential benefits of routine QOL assessment, which 
may include screening for unmet needs, facilitating communication, monitoring response to 
treatment, or prioritising problems (41, 53, 54).  Others have gone further by evaluating the 
benefits and burdens of QOL assessment directly with patients.  Table 2 below summarises 
some of these evaluations as related to oncology and palliative care – showing the benefits of 
routine QOL assessment, but also some potential burdens.  The study by Hill (55) shows the 
importance of having the correct content to QOL questionnaires, and to evaluate 
acceptability in a given patient group.  Mills (56) showed that QOL deteriorated more quickly 
in those who completed QOL tools weekly at home (compared to normal care), and 
concluded that feedback of QOL data to professionals is key to delivering benefit to patients.  
However, this conclusion conflicts with Velikova (57), who demonstrated a benefit to patients 
in the oncology outpatient clinic even when QOL data were not fed back to the oncologists.  
Taken together, these two findings suggest a possible role for the setting of questionnaire 
completion (home vs. clinic), which in turn affects the opportunity of patients to immediately 
discuss the issues with a healthcare professional.   The benefit may therefore be mediated by 
improved empowerment of patients to raise certain issues and therefore facilitation of 
communication.  This is supported by the findings of Detmar (58) (Table 2). 
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Table 2:   Summary of literature evaluating QOL tools alongside clinical care in oncology and palliative care. 
 
Author Design & Participants Summary of benefits (+) and burdens (-)  
Hill 2002a 
(59) 
Mixed methodology with quasi-
experimental evaluation of the 
MVQOLI in the hospice setting, 
and qualitative interviews with 
staff and patients. 
+ Improved understanding of the patient was achieved by 
giving nurses access to the patients’ QOL data. 
+ This better understanding resulted in clinically significant 
improvements in patients’ QOL.  
+ Many nurses were led to question things in more depth and 
consider the patients’ perspective 
Hill 2002b 
(55) 
Further discussion of qualitative 
findings from Hill 2002a (above) 
+ Assessment of QOL scores increased understanding 
between nurses and patients 
+ Nurses were surprised at how different their perception of a 
patient’s QOL was from that of the patient. 
+ Completion of questionnaires gave patients new insights 
- Revelations to the patient about their emotional, social and 
spiritual state were not always welcome or acceptable. 
Detmar 
2002 (58) 
Randomised crossover trial using 
the EORTC-QLQ-C30 questionnaire 
in the oncology outpatient setting. 
+ Physicians in the intervention group identified a greater 
percentage of patients with problems than those in the 
control group. 




Randomised trial using EORTC-
QLQ-C30, and HADS in the 
oncology outpatient clinic. 
+ Patients who has completed the questionnaires had better 
overall QOL subsequently.  This positive effect was seen 
regardless of whether results were fed back to physicians. 
+ A positive effect on patients’ emotional wellbeing was 
associated with feedback of QOL data to physicians. 
Mills 2009 
(56) 
Randomised trial of standard care 
vs. completion of an EORTC-QLQ-
C30 diary at home weekly for 16 
weeks, with no formal structure 
for feedback to professionals.  
Inoperable lung cancer patients. 
- Overall QOL deteriorated more rapidly in the intervention 
group, with only 23% reporting having shown the diary to a 
healthcare professional. Authors conclude that completion of 
QOL questionnaires can be detrimental without appropriate 
feedback to professionals. 
Key to abbreviations:  MVQOLI – Missoula-VITAS Quality of Life Index;  EORTC-QLQ-C30 – European Organisation 
for Research and Treatment of Cancer Core Questionnaire; HADS – Hospital anxiety and depression scale. 
 
These studies suggest that the design and implementation of QOL tools may determine 
whether benefit or burden is delivered to patients.  These issues are explored further below 
with reference to the current study.  
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1.3.6.   Objective and subjective information in the assessment of QOL 
 
When selecting or designing a questionnaire for the assessment of QOL it is important to 
consider the nature of the information obtained from a given tool.  QOL cannot be directly 
observed and so its assessment relies on gathering related information on issues such as 
levels of pain, mobility or distress (to name only a few).   A distinction is often made between 
objective and subjective information in assessments of this kind.   Clearly, subjective 
information always relies on the patient’s report.  By contrast, objective information is that 
which can be observed directly.  Ferrans notes that patient reported information does not 
necessarily imply that it is subjective (30).  For example, a patient may be asked to report the 
number of times they have vomited in the past 24 hours – objective information since it 
could also be directly observed.  It is the nature of the information that matters, rather than 
who reports it.   
 
This is important in the selection and design of QOL tools because it demonstrates that not all 
patient reported outcome measures provide subjective information.  But in order to 
recognise the centrality of subjectivity in QOL the focus should be on collecting subjective 
information.  For example, Ferrans goes on to note that the number of vomits in 24 hours 
does not adequately characterise the experience in terms of its impact on QOL. This could 
perhaps only be achieved by collecting subjective information (30).   
 
1.3.7.   Perception and evaluation of health status in the assessment of QOL 
 
In addition to the distinction between objective and subjective information, a further 
distinction has been described between so-called perceived health status and evaluation of 
health status (30).  Perceived status might be assessed by asking “what is your current level of 
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pain on a scale from 1 to 10?”.   Evaluation of health status could be elicited by asking “how 
satisfied are you with your current level of pain?”.  It is argued that an evaluation of health 
status provides more information and requires more complex cognitive processing that a 
perception (30).  Perceived and evaluated health status also behave differently over time and 
are influenced by different things.  For example, a patient reports a reduced pain score from 
7/10 to 3/10  (improvement in perceived health status).  However, over the same period the 
patient suffers multiple cancelled appointments, and so become less satisfied with their pain 
control, in spite of the improved pain score (worse evaluation of health status).  Alternatively, 
the pain score may remain the same at 7/10 (stable perceived status), but the level of 
satisfaction improves over time due to adaptation to illness (improved evaluation of health 
status).  Such altered responses resulting from changes in internal standards are known as 
‘response-shift’ (50). 
 
The wording of questions within a QOL tool can therefore affect the type of information 
received – which has particular importance when designing or selecting a tool for a given 
purpose.  For example, if a QOL tool is required for use in a therapeutic trial (where the 
primary purpose is to detect differences between treatment arms), then evaluations of 
health status are not usually of interest since they are more susceptible to change with 
variations in personal circumstance or illness adaptation.  This has been directly observed by 
those commenting on the use of QOL in cancer trials (60).   Conversely, if a QOL tool is to be 
used to facilitate clinical practice (where the primary purpose is to try and improve QOL for 
the respondent) then evaluative information may be more appropriate, since an individual’s 
personal satisfaction with their current health state is of greater importance (30). 
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1.4.   Summary of key points 
 
People diagnosed with multiple myeloma are surviving longer due to increased availability of 
novel treatments.  Myeloma has changed from an illness with a prognosis of just a few 
months, to an illness that patients can live with for many years.  Alongside improved survival 
and wider use of potentially toxic drugs comes a greater need to monitor the impact of the 
disease and treatment on QOL.  Monitoring of QOL alongside routine clinical care may 
highlight specific problems or demonstrate how QOL changes over time, and therefore allow 
clinicians and patients to target treatments to specific QOL concerns.  It is therefore 
becoming more important to monitor QOL within the routine care of myeloma patients. 
 
While there is no consensus definition for the term QOL, there is broad agreement that it is a 
subjective, multidimensional and dynamic construct involving at least physical, psychological 
and social domains.  The precise meaning can depend on the context in which it is used.  
HRQOL can be thought of as the part of overall QOL related just to health, but the two are 
closely linked since all domains of QOL may affect or be affected by health.  For this reason 
the present study adopts the term QOL throughout.  QOL cannot be measured according to 
the strictest definitions of measurement, and so the term assessment will be used. 
 
The subjective, multidimensional and dynamic properties of QOL pose a significant challenge 
for its assessment, and different QOL assessment tools provide different types of information 
depending on the wording of the questions within them (subjective/objective and 
perceived/evaluated information).  This can affect the choice of tool for a given purpose, and 
tools designed for use in research settings such as clinical trials may not be well suited to 
clinical use. 
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2.   Existing QOL tools for use in myeloma [PUBLICATION 1] 
 
This chapter presents a systematic review of the literature related to the development and 
validation of tools to assess the QOL of people diagnosed with myeloma.   
 
In 1996 the Nordic Myeloma Study Group were the first to validate a cancer-specific QOL tool 
in myeloma patients (the European Organisation for Research and Treatment of Cancer Core 
Questionnaire, EORTC-QLQ-C30) (61).  In 1999 a myeloma module was developed for use 
alongside the core questionnaire (the EORTC-QLQ-MY24) (62).  This was subsequently revised 
to the MY20 following further validation work (63).   In 2012 the Functional Assessment of 
Cancer Therapy (FACT) group developed a myeloma-specific tool (the FACT-MM), although a 
small sample was used in its development and validation to date has been limited (64).  The 
M. D. Anderson Symptom Inventory Multiple Myeloma module (MDASI-MM) has also been 
reported, but this is not a QOL tool since it captures only symptoms (65).   
 
These tools were designed primarily for use in therapeutic trials, and so have particular 
emphasis on treatment side effects.  A systematic review of QOL assessment in myeloma 
trials between 1990 and 2008 found only 15 trials reporting QOL as a study end point, and 
noted that this data had limited impact on published treatment recommendations (66).  
Moreover, 12 different instruments were identified across these 15 trials, highlighting the 
lack of consensus regarding the best instrument to use.    
 
The article that follows presents a systematic literature review published in 2012 as a 
preliminary step in the present study.  The review identifies all existing QOL tools developed 
or validated for use in people with myeloma, and evaluates them in terms of their ability to 
capture all the issues important to patients and their potential for use in clinical practice. 
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2.1.   Summary of key points and gaps in knowledge 
 
This section summarises the key points from the systematic review and other considerations, 
and makes the case that a new or modified QOL instrument is required for use in the clinical 
care of people with myeloma. 
 
1. Myeloma patients report physical, psychological and social impairments to QOL (4-6), 
which may be more severe and occur more frequently than in other cancers (8). 
 
2. Myeloma patients report unmet supportive care needs (7), which can be identified 
and prioritised using QOL assessment alongside clinical practice (41). 
 
3. Assessments of QOL in clinical practice can independently improve wellbeing in 
general oncology patients (57), and there are calls for this to become routine practice 
in the care of myeloma patients (4, 5, 9). 
 
4. The wording of questions within a QOL tool can affect the type of information it 
elicits (30), and so tools designed for use in therapeutic trials may not be well suited 
to clinical use (30, 60).  
 
5. The most extensively validated instruments currently available for the assessment of 
QOL in myeloma (61, 62) were designed for use in therapeutic trials and may not be 
comprehensive to all the issues important to patients (Publication 1). 
 
6. There is currently no QOL tool that has been developed specifically for use in the 
clinical care of people with multiple myeloma (Publication 1). 
 
7. There is a paucity of research to fully characterise the meaning of QOL from the 
perspective of people with multiple myeloma (Publication 1). 
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3.   Study aim and objectives 
 
3.1.   Aim 
 
To develop and validate an instrument (the MyPOS) to assess the QOL of patients with 
multiple myeloma that is suitable for use in the clinical setting. 
 
3.2.   Objectives 
 
1. To explore the issues important to QOL and develop a theoretical model of QOL from 
the perspective of people with multiple myeloma across all disease stages. 
 
2. To explore the views of myeloma patients and clinical staff towards existing QOL 
questionnaires. 
 
3. To explore the preferences of myeloma patients and clinical staff for the design and 
utility of QOL questionnaires for use in the clinical setting. 
 
4. To apply the theoretical model of QOL and preferences of patients and clinical staff 
to develop a prototype MyPOS questionnaire that is suitable for clinical use. 
 
5. To pre-test the prototype MyPOS to evaluate its acceptability to patients and make 
any necessary refinements prior to field testing. 
 
6. To field test the MyPOS in a clinically representative sample of myeloma patients and 
evaluate its psychometric properties. 
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4.   Theoretical and methodological considerations 
 
This chapter reviews the theoretical and methodological considerations whilst undertaking 
the current study, including a review of existing theory in the field of QOL research as 
relevant to the MyPOS development. 
 
4.1.   Qualitative research methods 
 
Qualitative research has been described as that which answers the ‘What?’ ‘How?’ or ‘Why?’ 
of a phenomenon, as opposed to quantitative research which answers the ‘How many?’ or 
‘How much?’ (67).  Qualitative enquiry maintains a focus on meaning and understanding and 
favours a naturalistic approach, referring to a dedication to studying a phenomenon in its 
natural state without any a priori assumptions about the nature of the phenomenon of 
interest.   
 
A number of different approaches and methods for conducting qualitative research have 
been described.  One of the most commonly cited approach in health research is ‘grounded 
theory’, which describes a specific method of iteration between data collection, analysis and 
theory generation that results in emergent theory that is entirely ‘grounded’ in the data (68).  
Some health researchers use ‘ethnographic’ techniques as a more naturalistic way of 
collecting and analysing qualitative data.  In ethnographic studies the researcher observes a 
naturally occurring phenomenon whilst seeking to minimise their own interference or impact 
(69).  For example, a researcher may want to explore the communication that takes place 
between a doctor and patient in a clinical encounter: one approach would be to interview the 
patient about their views on the consultation; a more naturalistic or ethnographic approach 
may be to record the consultation for subsequent analysis.  In this example the notion of 
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naturalism is idealistic, since the act of recording a doctor or patient clearly has the potential 
to change their behaviour and actions (67, 69).   In addition to interviews and recordings 
qualitative data might also include documents such as a personal diary or historical letters. 
Qualitative data can be organised together into stories or narratives as a way of 
understanding the phenomenon of interest in a so-called ‘narrative’ approach to qualitative 
research (70).   
 
Grounded theory, ethnographic and narrative studies each require a particular method of 
data interpretation and analysis.  Sandelowski describes an overlap and confusion over the 
meaning and use of these terms, arguing that many studies described as having a certain 
approach do not employ the required methods and would be better described as ‘qualitative 
description’ with overtones of grounded-theory, ethnography or narrative study (71, 72).  
Possible methods for qualitative data analysis including thematic content analysis, framework 
analysis and narrative analysis (73).  Sandelowski argues from within the purview of 
healthcare research, and recommends that when simply attempting to describe or 
characterise a particular phenomenon (such as QOL), then qualitative description with 
thematic content analysis should be used (71).  
 
Implications for the current study:  Qualitative methods are the obvious choice when 
attempting to characterise the meaning of QOL from the perspective of myeloma patients 
(Objective 1), and when exploring views and preferences for the design of QOL questionnaire 
for clinical use (Objectives 2 and 3).  The present study will therefore include a descriptive 
qualitative component using thematic content analysis to meet these objectives. 
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4.2.   Existing models of QOL 
 
Several theoretical models of QOL have been proposed to elaborate on the more basic 
definitions presented in Chapter 1.  An overview of such models is presented below, with an 
emphasis on those developed for use in healthcare, or cancer care where possible. 
 
4.2.1.   Linear models 
 
Wilson and Cleary (74) describe a model of QOL in cancer patients that attempts to forge a 
link between biological variables (such as tumour size) and QOL (Figure 3).  They propose that 
changes in biological or clinical variables lead to changes in symptom status, then functional 
change, altered health perceptions and finally changes in QOL.  Their model also recognises 
the contribution of individual factors (such as internal value systems) and environmental 
factors (such as social support) throughout this process.  The model is linear since it proposes 
a dominant causal relationship between each stage (biological variables cause symptom 
changes, which cause functional changes, and so on). 
 
Ferrans (75) proposes revisions to Wilson and Cleary’s model, suggesting that biological 
function may also be influenced by individual and environmental factors (note the lack of an 
arrow linking biological variables to individual or environmental factors, Figure 3).  Examples 
of individual factors affecting biological function might include behavioural characteristics 
such as motivation to exercise.  Examples of environmental factors affecting biological 
function include exposure to disease causing agents such as sunlight or radiation.  Ferrans 
also comments that the inclusion of ‘nonmedical factors’ (bottom right, Figure 3) is 
unnecessary since all nonmedical factors are either individual or environmental.  
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Figure 3:   Wilson and Cleary’s linear model linking clinical variables to QOL (74).   
 
4.2.2.   Interactive models 
 
Another criticism of Wilson and Cleary’s model is that the relationship between biological 
variables and QOL may be non-linear.  In so-called interactive models a change in one domain 
can lead to changes in multiple other domains.  For example, a change in symptom status 
(vomiting) may cause changes in biological status (renal failure), functional status 
(immobility) and psychological wellbeing (distress).   
 
McDougall (76) proposes an interactive model linking function and disability to QOL.  
McDougall’s model is based on the World Health Organization’s (WHO) International 
Classification of Functioning, Disability and Health (ICF) (77).  The ICF was published in 2001 
and has become a widely used system for classifying and coding health and disability (78).  As 
well as a coding system, the ICF presents a conceptual framework for understanding 
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with McDougall’s additions shown in green.  Note the interconnectedness of the core 




















Figure 4:  McDougall’s interactive model incorporating quality of life into the World Heath Organization’s model 
of Functioning, Disability and Health.  WHO model shown in blue (77), with McDougall’s additions in green (76). 
 
It has been noted by several authors that the ICF model alone does not include subjective 
dimensions such as well-being and quality of life (76, 79, 80).  McDougall sees QOL as a 
composite factor emerging from all factors within the ICF model, arising and continually 
interacting with all components and changing over time (as represented by ovals 
circumventing the core model, Figure 4) 
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4.2.3.   Expectation or gap models 
 
Both liner and interactive models are useful in their ability to link biological variables and 
function with QOL.  Such models are popular with healthcare professionals since they 
demonstrate how familiar objective factors such as biology and function might be linked with 
the more nebulous concept of QOL.   In order to make the leap from biology to QOL, both 
models above suggest that some degree of human perception, judgement or interpretation is 
required.  But what psychological processes are at work when these perceptions are formed?  
Put simply – what is going on inside the ‘General Health Perceptions’ box in Wilson and 
Cleary’s model? (Figure 3). 
 
Calman (81) observed that people often express QOL in terms of satisfaction or contentment.  
From this he hypothesised that QOL in cancer patients is determined by “the difference, or 
the gap, at a particular period of time between the hopes and expectations of an individual 
and that individual’s present experiences”.   If an individual’s expectations were higher than 
their current health state, then QOL would be low.  If expectations were lower than current 
health then QOL would be good.  Calman points out that this model has therapeutic 
implications.  If a patient reports low QOL, then the clinician has two options – either improve 
the health state, or possibly try reducing expectations.  This has particular relevance in the 
realm of incurable disease and palliative care, where the health state cannot always be 
modified, but managing expectations about their health and prognosis may help restore life 
quality (81). 
 
Calman’s model does not refer directly to objective factors such as biology and physical 
function, but nor are these irrelevant.  Biology, function or environment might all have a role, 
but it is the expectations about these things that will ultimately determine QOL.  Gap models 
are not mutually exclusive to the linear and interactive models presented earlier.  For 
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example, Calman’s model could sit within Wilson’s linear model, as an explanation of the 
‘General health perception’ box (Figure 3).  Wilson explains what is appraised to arrive at 
QOL, whereas Calman explains how individuals carry out this appraisal.  
 
4.2.4.   Mediational models 
 
A number of other models have been presented that explore how individuals appraise their 
objective health state to arrive at a perceived QOL.  Those working in psychology and mental 
health have suggested that personal characteristics such as self-efficacy, self-respect or 
autonomy are the key mediators of this appraisal process, and so ultimately determine 
perceived QOL (82-85).   
 
These have become known as mediational models, with one of the first reported by Zissi (84) 
in the field of mental health.  Zissi assessed a number of so-called ‘objective indicators’ 
(leisure activities, social relations, physical health etc.), and also some personal characteristics 
(self-concept and personal autonomy) and correlated these with overall subjective QOL.  
Improved personal autonomy and heightened self-concept were significantly associated with 
better QOL, but no relationship between QOL and the ‘objective indicators’ was found.  This 
lead Zissi to propose that self-concept and autonomy mediate the personal evaluation of 
objective factors in making personal judgements about well-being and QOL (84) (Figure 5). 
 
Subsequent meditational models have been proposed to conceptualise QOL in cancer 
patients.   Maurice-Stam (82) proposes that developmental milestones, coping mechanisms 
and social support act as mediating factors in the appraisal of QOL for survivors of childhood 
cancer.  Smith (83) looked at survivorship and suggests that the QOL of those who recover 
from non-Hodgkin’s lymphoma is mediated by post-traumatic stress and post-traumatic 
growth, to arrive at subjective perceptions of physical, emotional and social wellbeing.  






















Figure 5:   Zissi’s mediational model of quality of life (84) 
 
4.2.5.   Needs-based models 
 
Some authors have conceptualised QOL in terms of the hierarchy of human needs proposed 
by Maslow (86, 87).  At the bottom are the most fundamental physiological needs (sleep, 
food, water), progressing up through safety (shelter, employment, resources), love, esteem 
and finally self-actualisation (morality, creativity, spontaneity).  Higgs (88) reports a model of 
QOL that places need-satisfaction at its core and proposes four domains of QOL in old age 
that are based on the need for control, autonomy, pleasure and self-realization.   Higgs 
develops a QOL tool based on this model (the CASP-19), and demonstrate its empirical 
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4.2.6.   Phenomenological models 
 
An important reason for building conceptual models of QOL is that they provide a theoretical 
framework upon which assessment tools may be developed and validated.  Many of the 
models discussed thus far were postulated specifically to satisfy these ends, and have led to 
the development of structured questionnaires.  However, some have argued that such 
structured tools with pre-determined questions ignore the centrality of subjectivity in QOL.  
O’Boyle (89) suggests that only the individual can define what is important to QOL, and so 
structured tools should not be used in its assessment.  This lead to the development of a QOL 
assessment tool (the Schedule for the Evaluation of Individual Quality of Life (90), or SEIQoL) 
in which respondents define all the domains themselves, and weight them according to 
relative importance.    
 
The SEIQoL has been used and validated in many different patient groups including non-
cancer (91-95), oncology (96, 97), palliative care (98) and haemato-oncology (99-101).  
However, authors often report difficulties with feasibility (comprehension and time taken to 
complete) and problems comparing scores longitudinally due to the changing domains used. 
 
Implications for the current study:  The range of models presented above highlights the 
richness of existing work in the field of QOL research.  The development process for the 
MyPOS should not attempt to ‘re-invent the wheel’, but instead to build on existing work and 
potentially adapt or develop existing models to apply more specifically to people with 
myeloma.  The elements of existing theory that might apply when developing the MyPOS 
were not known at the study outset, but are discussed below alongside the study findings. 
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4.3.   A new tool or an adaptation of an existing tool? 
 
In a similar way to the development of QOL models, the development of QOL questionnaires 
is a well-trodden path.  A range of existing QOL tools has been validated for use in myeloma, 
but these are not always focused on the priorities of patients, and no instrument has been 
developed specifically for use in the clinical care of myeloma patients (Publication 1). 
 
A pan-European survey of palliative care professionals identified over 100 different tools and 
suggested that users require the number of tools to be rationalised (102).  Would it be 
appropriate to add a new tool to an already overcrowded marketplace?  One reason for the 
proliferation of QOL tools is the need to develop instruments that are specific to a given 
disease, stage of disease (newly diagnosed / relapsed / palliative) or treatment group 
(chemotherapy / radiotherapy / off treatment) – since there may be different issues relevant 
in different contexts.  A possible solution is to use a core questionnaire (containing issues 
relevant at all stages) with supplementary modules for different tumour groups or stages.  
This approach has been specifically proposed for clinical QOL tools (103), and has been 
adopted by the European Organisation for Research and Treatment of Cancer (EORTC) who 
have developed a core cancer questionnaire (EORTC-QLQ-C30) with modules for different 
tumour groups, treatments modalities and phases of disease (104).  The EORTC tools are 
designed specifically for use in therapeutic cancer trials, and may not be well suited to clinical 
practice (Publication 1), although this model could be transposed into more clinically 
applicable tools. 
 
The EORTC has published a myeloma module (the MY24 and MY20 (62, 63)), and a high-dose 
treatment module (HDC19) has also been validated for use in bone marrow transplant 
recipients (in a sample containing myeloma patients (105)). Their finished tools highlight 
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some important problems with this model – the complete myeloma instrument (core plus 
module) has 54 items, and the high-dose treatment tool has 49 items.  The increased length 
of these tools increases burden on patients, possibly resulting in reduced uptake.  Using 
different modules at different disease stages may also make comparisons difficult over time, 
reduce interpretability, and increase administrative burden on staff.  All of these factors can 
impede effective implementation of a new tool into clinical practice. 
 
However, the advantages of developing modules to an existing questionnaire are not 
inconsiderable.  Existing or ‘core’ questionnaires have inevitably undergone a degree of 
validation already, and so their validity in certain groups may already have been 
demonstrated.  It may be foolish to discard all of this preceding work in favour of a 
completely new tool. 
 
Implications for the current study:  The content and layout of the MyPOS remained flexible 
at the outset of the study.  The decision whether to design a completely new questionnaire 
or adapt an existing one was guided by the priorities of patients and clinical staff identified 
with the first phase of present study, and so is discussed alongside the study findings below.    
 
4.4.   Intended utility of the MyPOS 
 
It is important to consider the intended utility of the MyPOS, since its utility should guide the 
design of the tool, and methods used for validation (106).  Table 3 summarises the intended 
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Table 3:  Outline of the intended utility of the MyPOS and implications for the current study 
 
Intended utility: Implications for the current study: 
Setting:  The MyPOS will be used in 
hospital outpatient clinics and ward 
settings. 
 The MyPOS should be validated and tested in the same settings as 
its intended use (hospital clinics and wards) 
 The MyPOS should be validated across multiple hospital sites to 
ensure transferability. 
Respondents:  The MyPOS will be 
completed by patients with myeloma 
across all disease stages. 
 The MyPOS should be validated in a clinically representative sample 
of patients at all disease stages. 
 The MyPOS should be acceptable to patients across all disease 
stages 
Care providers:  The MyPOS will be 
interpreted by care providers from a 
range of professional backgrounds. 
 Appropriate healthcare professionals should be consulted during the 
development of the MyPOS – including those from medical, nursing 
and allied health backgrounds. 
Purpose 1):  The MyPOS will help 
care providers to screen for 
important clinical problems 
 The questions within the MyPOS should be based on the most 
important and clinically relevant problems from the perspective of 
patients and healthcare professionals. 
Purpose 2):  The MyPOS will be used 
to facilitate communication between 
patients and care providers 
 The MyPOS should be centred on the problems and concerns most 
important to patients, and most relevant to clinicians.  
 
 
4.5.   Future implementation of the MyPOS 
 
The present study is concerned with the development and validation of the MyPOS, and does 
not directly address implementation into practice.  However, it is important to consider 
possible barriers and facilitators to implementation, since these may affect the design of the 
tool itself.  Davis and Cella present a systematic literature review to identify barriers and 
success factors related to implementing QOL assessment in clinical practice (107). Table 4 
summarises the findings of this 2002 review, with additions from the more recent literature. 
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Table 4:   Summary of barriers and facilitators to the implementation of QOL assessment in oncology and 
palliative care practice.  Adapted and updated from Davis and Cella (107). 
 
Barriers to implementation of QOL assessment in clinical practice References 
Provider inexperience 
 Lack of familiarity with assessment tools 
 Lack of knowledge about the usefulness of results 
 Lack of training on interpretation of results 
(54, 102, 107, 
108) 
Methodological barriers 
 History of methodologically flawed tools 
 Limited ability of instruments to detect clinically meaningful changes 
 Limited ability of instruments to compare scores across tools  
(107, 109) 
Feasibility / logistic barriers 
 Administrative burdens 
 Delayed presentation of results limiting relevance for treatment planning 
 Time and other resource constraints 
(54, 107-109) 
Perceived negative impact on patients 
 Concerns about time burden, intrusion or causing distress to patients 
 Concerns about patient confidentiality 
(54, 108, 109) 
Facilitators for implementation of QOL assessment in clinical practice References 
Acceptable set of tools 
 Clear set of tools from which to choose, and appropriate training available 
 Streamlined assessments possible 
(54, 107, 109, 
110) 
Clinical relevance and ease of use 
 Tools that provide clinically relevant and holistic assessments 
 Clear demonstration of how results can be used to guide treatment 
 Administration platform that minimises staff burden and provides feedback 
 Importance of brief tools 
(102, 107-110) 
Buy-in from staff and patients 
 Staff knowledge and positive attitude about routine QOL assessments 
 Staff buy-in based on clinical relevance of assessment 
 Patient buy-in regarding usefulness in guiding communication  
(107) 
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Implications for the current study:  It is important that the MyPOS captures the concerns 
most important to patients and clinicians.  Interviews and focus groups of patients and 
clinicians will be used in the development of the MyPOS, and the selection of items guided by 
the priorities of its end users.  The MyPOS should be as brief as possible, to reduce 
administrative burden on staff and time burden on patients.  Many myeloma patients are 
elderly (Figure 1), and may also suffer from cognitive difficulties – further highlighting the 
need for a brief tool that is easily comprehensible.  The MyPOS will be evaluated in terms of 
comprehension using cognitive interviewing of patients in different age groups and different 
degrees of frailty. 
 
4.6.   Psychometric and clinimetric approaches 
 
The terms psychometric and clinimetric are often used when discussing the development of 
patient reported outcomes.  In simple terms, psychometrics refers to the application of 
mathematical techniques to the measurement of psychological constructs (such as 
intelligence or personality).  Clinimetrics is a term introduced by Feinstein in the 1980’s, and 
refers to the theory and technique of developing and refining such tools for clinical use.  
Proponents of the clinimetric / psychometric distinction observe that psychometric scales 
attempt to measure a single characteristic using multiple items, whereas clinimetric scales 
summarise multiple clinical characteristics with a single score, in order to make the tool more 
clinically useful (111).   
 
Feinstein argued that psychometric scales are fundamentally different to clinical scales such 
as those quantifying QOL, and suggested that the development and validation of 
psychometric and clinimetric scales should proceed using different methods (112).  However, 
other prominent authors such as Streiner have since argued that this is a false and unhelpful 
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distinction, with clinimetrics merely forming part of what psychometrics already seeks to 
achieve (113).   
 
In practice, the methods used to develop and validate a tool should be guided by its intended 
purpose or utility.   For example, if a QOL tool is required to detect changes over time in 
therapeutic trials, then validation should include (at least) psychometric evaluation of 
responsiveness.  By contrast, a tool designed to screen for depression in clinical practice 
would require evaluation of its ability to identify depressed patients (sensitivity and 
specificity), and comparison against clinical assessment. 
 
The example of a depression-screening tool lies at the clinimetric end of the psychometric-
clinimetric spectrum.    However, tools cannot always be polarised to one end of this 
spectrum or another.  A QOL tool for use in clinical practice may require good clinimetric 
properties (e.g. ability to detect and flag important clinical problems), but also good 
psychometric properties (e.g. ability to monitor changes in QOL over time during treatment).  
The development of such tools should proceed along the lines of its intended utility, and so 
may require elements of both psychometric and clinimetric validation (111).   
 
Implications for the current study:  For the reasons presented above, both clinimetric and 
psychometric approaches will be employed to some degree in the development of the 
MyPOS.  The MyPOS’s ability to flag important clinical problems will by ensured by involving 
patients and clinicians in the development of the item pool; cognitive assessment with 
patients will ensure the MyPOS is acceptable and easy to understand; and psychometric 
validation will ensure the MyPOS is a reliable tool with good measurement properties. 
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4.7.   Causal and indicator variables 
 
Some authors have observed that the items used in QOL scales can be divided into those 
based on causal and indicator variables (46, 106, 111, 114).  Causal variables are those that 
can themselves cause a change in QOL (e.g. vomiting).  Severe vomiting is likely to affect QOL, 
but the converse is unlikely to be the case – the level of QOL is unlikely to affect vomiting 
(106).   By contrast, indicator variables merely reflect the level of the QOL, and there need 
not be a causal relationship in either direction.  An example of an indicator variable would be 
mood – as mood improves so does QOL, and as mood reduces so does QOL.  In statistical 
terms, a good indicator variable is one that is closely correlated with QOL (114).   In practice, 
however, many variables are not so easily categorised as causal or indicator.  For example – 
worse pain is likely to cause worse QOL, but could worse QOL cause worse pain? – possibly, 
although this is perhaps less likely.  So does pain merely reflect the level of QOL, or is it 
related in a causal way? Clearly there are arguments for both perspectives, and the degree to 
which each is true may vary between individuals.  Although the causal / indicator distinction 
is not always clear, most disease symptoms and side effects of treatment behave to some 
degree as causal variables (the symptoms causes worse QOL, with the reverse less often 
true).  In practice therefore, QOL tools often contain causal variables, since symptoms and 
side effects are often of particular interest (111).  Many existing QOL instruments contain a 
mixture of both types of variables and often is not obvious to which category each belongs 
(106). Some have commented that the differences between causal and indicator variables 
underpin many of the differences between clinimetric and psychometric scales (114). 
 
The causal / indicator distinction is important when developing a QOL tool because 
mathematical models used in scale development often assume that all items are indicator 
variables and depend solely on the latent variable: when QOL is ‘high’ all items will be also be 
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‘high’.  Methods such as factor analysis used in scale development analyse correlations 
between items, with the aim of grouping together highly correlated items and providing 
evidence of an underlying factor/domain structure to QOL.  For example, a factor analysis 
may extract items about nausea, pain and diarrhoea as highly correlated with each other – 
the assumption then follows that these three items represent an underlying domain (e.g. 
‘physical symptoms’) of QOL.  This can be used in the process of item reduction, since items 
that do not correlate well with any domain may be excluded as poorly performing items (for 
more details on item reduction see section 7.5 below).  So in this example the factor analysis 
has identified ‘physical symptoms’ as a domain of QOL, and assumes that nausea, pain and 
diarrhoea are correlated together because of an underlying relationship to this domain and 
hence to QOL.  However, this assumption does not always hold for causal variables based on 
symptoms.  For example, nausea, pain and diarrhoea may correlate with each other because 
they often occur together in a symptom cluster (e.g. when starting chemotherapy).  Their 
grouping together in a factor analysis is a reflection of changes in treatment, and says little 
about an underlying relationship to QOL (106).   This has led some to assert that factor 
analysis is “largely irrelevant as a method of scale validation for those QOL instruments that 
contain causal variables” (46).  Others take the more permissive view that “aggregating 
symptoms or side effects [causal variables] into a summated scale should be done with 
greater caution than other aspects, such as depression [indicator variables]” (104).  This more 
permissive view is often taken in practice, and the causal / indicator distinction seems rarely 
recognised in clinical scale development (106).  
 
Implications for the current study:  To exclude all causal variables, or completely disregard 
factor analysis in the development of the MyPOS would be a mistake.  Patients and clinicians 
may report that a particular variable is central to QOL or crucial in clinical practice – should 
this item then be excluded from the MyPOS if it is considered to be a causal variable?  Clearly 
not, since the intended utility is within clinical practice, and so some items may be essential 
Chapter 4: Theoretical and methodological considerations 
68 
on clinical grounds.  So if causal variables are included should factor analysis be avoided in 
the development process?  This too would be a mistake, since it may still provide useful 
information.  Factor analysis has limitations when causal variables are included, but the 
answer is not to discard this method completely, but instead to bear these limitations in mind 
when interpreting the emergent factor structure.  In the present study, a factor analysis will 
be carried out to identify groups of MyPOS items that correlate well or group together.  This 
emergent factor structure will then be interpreted by those with clinical knowledge of the 
topic, to appraise whether causal variables are loading together due to symptoms clusters, or 
whether a true relationship exists with underlying QOL.  By bringing clinical knowledge to 
bear and asking why a group of items might be correlated, a factor analysis can still inform 
the development of the MyPOS.  The author of the present study has experience of working 
clinically with myeloma patients in inpatient, outpatient and hospice settings, and so is well 
placed to carry out this kind of analysis.  
 
4.8.   Summary of key points 
 
The design of the MyPOS questionnaire should be driven by the views and preferences of 
myeloma patients and clinical staff, but should also take account of existing theory and 
models of QOL to avoid re-inventing the wheel.  The MyPOS development process will 
require the use of qualitative research methods to understand the meaning of QOL and build 
a theoretical model, followed by quantitative methods for psychometric testing.  The 
intended utility and implementation of the MyPOS should inform its development, to ensure 
the final questionnaire has properties that are well suited to clinical applications.  The 
distinction between causal and indicator variables should be considered during the 
development of the MyPOS, with both clinimetric and psychometric strategies required to 
produce an effective clinical tool. 
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5.   Overview of study design and methods 
 
Stages of development of the MyPOS are based on accepted standards for the development 
of patient reported outcomes, as outlined by the European Organisation for Research and 
Treatment of Cancer (EORTC) (104).  Figure 6 gives an outline of the study methods, with full 







































Phase II:  Construction and pre-testing of the MyPOS  
 
a) Use the above findings to develop a prototype MyPOS questionnaire. 
 
b) Pre-test the prototype MyPOS using cognitive interviewing in a purposive 
sample of myeloma patients and make any necessary refinements. 
Phase III:  Field testing the MyPOS 
 
a) Test the psychometric properties of the MyPOS in a national multi-centre, 
























Phase I:  QOL issues and preferences for questionnaire design 
 
a) Semi-structured qualitative interviews in a purposive sample of myeloma 
patients across all disease stages to explore the issues important to QOL. 
 
b) Semi structured qualitative interviews in a separate purposive sample of 
myeloma patients to appraise a range of existing QOL questionnaires. 
 
c) Focus groups of myeloma patients and clinical staff to explore the issues 
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6.   Qualitative study of views on QOL [PUBLICATION 2] 
 
The publication that follows reports a qualitative study exploring the issues important to QOL 
from the perspective of people with multiple myeloma, and the views of patients and clinical 
staff towards a range of existing QOL questionnaires and their use in clinical practice. The 
article presents a theoretical model of QOL from the perspective of people with myeloma, 
which subsequently guides the content of the MyPOS questionnaire.   
 
This chapter addresses Objectives 1, 2 and 3 of the overall thesis, repeated below for clarity: 
 
1. To explore the issues important to QOL and develop a theoretical model of QOL from 
the perspective of people with multiple myeloma across all disease stages. 
 
2. To explore the views of myeloma patients and clinical staff towards existing QOL 
questionnaires. 
 
3. To explore the preferences of myeloma patients and clinical staff for the design and 
utility of QOL questionnaires for use in the clinical setting. 
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7.   Development and validation of the MyPOS 
[PUBLICATION 3]  
 
The publication that follows reports the development, pre-testing and psychometric 
validation of the MyPOS questionnaire.   It was considered preferable to modify an existing 
questionnaire rather than design a completely new tool, to take advantage of existing 
development work and items that had been field-tested and used in practice.  The qualitative 
findings (Publication 2) indicated that the earlier systematic review (Publication 1) had 
identified no suitable tool for adaptation, so tools outside the scope of the review were 
considered.  The MyPOS was developed as an adaptation of the Palliative Care Outcome 
Scale (POS) and its accompanying symptoms scale (POS-S), as the best available fit for the 
qualitative data (115).  A prototype MyPOS was pre-tested and refined using cognitive 
interviews in a purposive sample of myeloma patients.  The MyPOS was then field tested to 
evaluate its psychometric properties in a national multi-centre survey of myeloma patients 
recruited from 14 hospital trusts across England. 
 
This chapter addresses Objectives 4, 5 and 6 of the overall thesis, repeated below for clarity: 
 
4. To apply the theoretical model of QOL and preferences of patients and clinical staff 
to develop a prototype MyPOS questionnaire that is suitable for clinical use. 
 
5. To pre-test the prototype MyPOS to evaluate its acceptability to patients and make 
any necessary refinements prior to field testing. 
 
6. To field test the MyPOS in a clinically representative sample of myeloma patients and 
evaluate its psychometric properties. 
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8.   Overall discussion and integration  
 
8.1.   Summary of main findings 
 
This thesis reports the development and validation of the MyPOS – the first QOL assessment 
tool designed specifically for use within the clinical care of people with multiple myeloma.  
Initial qualitative work identified the issues most important to the QOL of myeloma patients, 
and found that symptoms had an indirect effect on QOL, affecting overall QOL only if they 
impacted on more fundamental domains.  Health service factors emerged as particularly 
important, and sexual dysfunction was highlighted by patients and healthcare professionals 
as a difficult issue to raise in a typical clinical encounter.  No existing QOL tool captured all of 
these findings, so the existing POS and POS-S questionnaires were modified to form the 
preliminary MyPOS, since these existing tools contained items and scaling that were a good 
fit for the qualitative findings and model of QOL.  The preliminary MyPOS was refined using 
cognitive testing to improve acceptability, and a cross sectional survey demonstrated that the 
MyPOS had good internal consistency, structural validity and construct validity. 
 
The initial qualitative study (Publication 2) presents the first comprehensive model of the 
QOL in myeloma, with input from patients across all disease stages.  The model identifies 
biological status, treatment factors, symptom status, activity & participation, emotional 
status, support factors, expectations, adaptation & coping and spirituality as factors 
important in determining QOL.  Symptoms were found to have an indirect effect on QOL, only 
affecting overall QOL if they impacted upon activity & participation, emotional status or 
support factors.  Issues related to the quality and accessibility of healthcare emerged as 
particularly important to QOL from the perspective of myeloma patients, but are absent from 
the best existing questionnaires developed or validated for use in this group.  Sexual function 
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was raised as an important issue by patients, but is difficult to broach in a typical clinical 
encounter for both patients and clinicians, suggesting that inclusion in clinical QOL 
questionnaire would be useful to help flag hidden problems and facilitate better care.  
Patients and staff both expressed preferences for clinical QOL questionnaires to be no more 
than 2 pages long, present information in a way that is easy to assimilate, and include a 
mixture of structured and open questions to improve clinical utility and help focus the goals 
of care on what is most important to patients. 
 
The construction of the preliminary MyPOS was grounded in the theoretical model of QOL 
and other findings from the qualitative study.  The MyPOS was developed as an adaptation of 
the existing POS questionnaire and its symptoms scale the POS-S, to take advantage of 
existing validation work.  The preliminary MyPOS contained a mixture of existing items from 
the POS and newly written items, with both structured and open questions.   The MyPOS 
symptom scale aligns with the theoretical model of QOL by requiring respondents to consider 
the effect of each symptom on activities and concentration.  The MyPOS also contains items 
about respondents’ sex life and healthcare factors that are absent from the best validated 
existing myeloma QOL questionnaires.    
 
The 33-item preliminary MyPOS was refined using cognitive interviews to a 30-item tool 
taken forward for psychometric testing.  The MyPOS was acceptable to patients, with a mean 
time to complete of 7 minutes 19 seconds and only 0.58% missing MyPOS items overall.  
Internal consistency was high with a Cronbach’s α of 0.89.  Exploratory factor analysis 
identified three subscales: Symptoms & Function; Emotional Response and Healthcare 
Support, which align with the structure predicated by the theoretical model.  All items loaded 
onto the subscale predicted by the model, and items about symptoms and function loaded 
together in a single subscale, as would be predicted when asking respondents to consider the 
effect of symptoms on activities and concentration.    MyPOS total scores were higher (worse 
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QOL) in those with relapsed or progressive disease compared to newly diagnosed or stable 
disease and were worse in those currently receiving chemotherapy. Scores in the MyPOS 
Symptoms & Function subscale were higher (worse QOL) in those with worse ECOG 
performance status.  Good convergent and discriminant validity were demonstrated against 
associated subscales of the EORTC-QLQ-C30 and MY20 questionnaires, which have 
undergone the most extensive prior validation in myeloma patients. 
 
8.2.   Generation of theoretical model and MyPOS questionnaire 
 
This is the first study to fully characterise the components of quality of life from the 
perspective of people with myeloma.  The systematic literature review (Publication 1) 
identified only a small number of previous studies using qualitative methods with myeloma 
patients, which had explored related issues such as lived experience (7, 116-118), trauma and 
post-traumatic growth (119) and distress (120), but none had specifically explored QOL.   
 
The theoretical model presented in Publication 2 was adapted from a model presented by 
Wilson and Cleary (74), which is one of the most widely used and reported models in the 
literature (121).  The rationale and process for adapting the model are described in 
Publication 2, but the modifications merit more detailed discussion since they cast light on 
how the current study contributes to the field.  The two models are presented side-by-side 
below for ease of comparison (Figures 7 and 8). 
 
Wilson and Cleary’s model (Figure 7) was intended for use across a range of different 
diagnoses, and so contains only overarching domains (e.g. biological variables, symptom 
status, and functional status).  The adapted model (Figure 8) adds flesh to the bones of 
Wilson and Cleary’s model by including disease-specific issues important to myeloma 
patients. These myeloma-specific issues formed the basis of item generation for the MyPOS. 
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Figure 7:  Wilson and Cleary’s model linking clinical variables to overall QOL (74) 
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8.3.   Interconnectedness of QOL domains 
 
The model of QOL developed in the present study shows QOL domains as interconnected 
(e.g. biological status  symptom status OR emotional status OR activity & participation), 
whereas Wilson and Cleary’s model is linear, with domains linked by dominant causal 
relationships in a linear way (biological variables   symptom status  functional status, and 
so on).  The interconnected nature of QOL domains is supported by data from the qualitative 
interviews (Publication 2, Figure 1). 
 
The interconnectedness of QOL domains has implications for the development and validation 
of QOL questionnaires such as the MyPOS.  If QOL domains are interconnected then it follows 
that respondents may answer questionnaire items in an interconnected way.  For example, a 
question about pain may be affected by the respondent’s mood, even if the question does 
not ask about their mood.  In other words, the response to an item in one subscale (e.g. 
MyPOS Symptoms & Function subscale) may be influenced by variables in a different subscale 
(e.g. the MyPOS Emotional Response subscale).  This has implications for the mathematical 
techniques used in questionnaire development and validation.  The MyPOS was developed 
using exploratory factor analysis to identify underlying subscales (Publication 3).  Within the 
factor analysis a technique called rotation was employed to improve the simplicity of the 
resulting factor structure and ensure that items load more definitively onto the factors that 
emerge.  The Promax method of rotation was used, which was chosen since it is a type of 
oblique rotation (as opposed to orthogonal rotation).  The advantage of oblique over 
orthogonal rotation is that oblique solutions often have better structural simplicity (122).  
However, oblique rotations result in factors that may be correlated to some degree, and so 
should be employed only where the underlying theory suggests some interconnectedness of 
the domains being investigated, as was the case during the development of the MyPOS. 
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The interconnectedness of QOL domains in Figure 8 echoes other published models such as 
that presented by McDougall (76) (Figure 4).  McDougall’s model shows body function, body 
structure, activities and participation as affected by health conditions, environmental factors 
and personal factors.  It was adapted from the WHO ICF model of functioning and disability 
(77), which defines activity as functioning at the level of the individual (e.g. ambulation or 
self-care), and participation as the functioning of a person within society (e.g. interpersonal 
relationships or professional roles).  The ICF model and McDougall’s adaptation both present 
activities and participation as separate and distinct domains (Figure 4), whereas the model 
presented in the present study represents them as a single domain (Figure 8).  Activities and 
participation were united into a single domain since the qualitative data suggested they both 
had the same close and direct relationship to overall QOL:  changes in mobility or ability to 
self-care had a direct impact on QOL, as did a change in interpersonal relationships or work 
life.  The domain ‘Activity and Participation’ replaces Wilson and Cleary’s domain ‘Functional 
Status’ to more accurately capture the issues described as important by participants of the 
qualitative interviews. 
 
8.4.   Role of symptoms in QOL 
 
The qualitative component of the present study showed that physical symptoms only 
affected overall QOL if they first affected more fundamental domains such as activity, 
participation or emotional status, which were more closely related to QOL.  (Publication 2, 
Figures 1 and 3).  This guided the design of the MyPOS questionnaire, with MyPOS symptom 
items worded specifically to capture the impact of symptoms on activities and concentration, 
rather than simply capturing symptom status (Publication 3). 
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The ability of the MyPOS to capture the impact of symptoms on other aspects of life is an 
important strength, since it maintains focus on what is most important to patients.  The 
systematic review (Publication 1) showed that most existing QOL tools validated for use in 
myeloma focus just on symptom status, with only a small number requiring an evaluation of 
the impact of symptoms (Publication 1, Table 4).  The review identified the EORTC-QLQ-C30 
with its myeloma module the MY24/MY20 as the most extensively validated existing QOL 
questionnaires in myeloma patients, but the symptom items in both these tools capture only 
health status (61, 62). 
 
8.5.   Domains most fundamental to QOL  
 
The qualitative interviews suggested that emotional status, activity & participation and 
support factors were the domains most closely related to overall QOL.  This is represented in 
the model as direct lines between these domains and overall QOL.  This contrasts with 
biological status, treatment factors and symptom status, which only affected overall QOL if 
they first impacted on the more fundamental domains (Figure 8). 
 
The more fundamental domains of emotional status, activity and participation and support 
appeared to form the essence of QOL itself, whereas biological status, treatment factors and 
symptom status merely impacted upon QOL in certain circumstances.  This distinction is 
reminiscent of the difference between indicator and causal variables described by Fayers (46, 
106, 111, 114), as discussed in Chapter 4 above.  MyPOS items based on the fundamental 
domains of emotional status, activity & participation or support factors should therefore 
behave more like indicator variables, since these merely reflect the level of QOL (when the 
variable improves so does QOL, and vice versa).  By contrast, MyPOS items based on 
biological status, treatment factors and symptom status should behave more like causal 
variables (since these factors can only cause a change in QOL).   
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8.6.   Causal and indicator variables and the MyPOS 
 
Guidelines published by the EORTC group recommend that factor analysis can be used during 
development and validation of QOL scales, but suggest caution when the scale contains 
causal variables, for the reasons discussed above in Chapter 4 (104). Fayers takes the less 
permissive view that factor analysis should be avoided in the validation of QOL scales 
containing causal variables such as symptom items (46).   This requires some reflection since 
the MyPOS contains symptom items and an exploratory factor analysis was used in its 
development (Publication 3, Table2).  The finished MyPOS contains three subscales:  
Symptoms and Function, Emotional Response and Healthcare Support.   All items in the latter 
two subscales are based on the domains most fundamental to QOL, and so are likely to 
behave as indicator variables.  However, the Symptoms and Function subscale contains a 
mixture of items about activity, participation and symptoms.  Why did the symptoms items 
load together into a single subscale with items about activities and participation?  This is 
likely to be due to the wording of the MyPOS symptom items, which require respondents to 
report not just the severity of each symptom but to evaluate the impact on ‘activities and 
concentration’.  Under normal circumstances symptom items in QOL scales will behave as 
causal variables, but the MyPOS symptom items are really asking about ‘activities and 
concentration’, and so they may behave more like more like indicator variables, since the 
model suggests that activities and concentration are more fundamental, and may form the 
essence of QOL itself from the patients’ perspectives.   
 
8.7.   Importance of treatment factors to QOL 
 
Many participants of the qualitative interviews raised treatment-related issues as impacting 
on their QOL.  Examples included treatments such as chemotherapy, investigations such as 
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bone marrow aspiration, or other intrusions such as repeated hospital visits or admissions 
(Publication 2, Figure 3).  Other qualitative studies identified in Publication 1 also identified 
treatment factors as important to the lived experience of myeloma patients (7, 117, 118).   
 
Treatments are not captured in Wilson and Cleary’s model of QOL (74), so a new domain for 
‘treatment factors’ was added  to reflect the particular importance of these issues to people 
with myeloma.  Much like biological factors, treatment factors did not directly affect QOL, but 
were often the cause of symptoms or functional impairments, ultimately leading to changes 
in QOL.  This is reflected in the model (Figure 8).  Specific examples from the qualitative data 
of how treatments affected QOL are shown in Publication 2, Figure 1.   
 
The indirect effect of treatments on QOL affected the choice of items for the MyPOS.  Much 
like for symptoms, the MyPOS does not contain items simply asking about treatment status 
(e.g. ‘Over the past week have you received chemotherapy?’), since the presence or absence 
of a given treatment is not the most important thing when considering QOL.  Instead, the 
MyPOS was constructed to capture how treatments might affect the more fundamental 
domains of QOL, such as Emotional Status.  Examples include the emotional impact of 
treatment side effects such as hair loss or weight gain (‘Have you been worrying about your 
physical appearance?’), or the impact of immunosuppressive treatments (‘Have you been 
worrying about infections?).  This again ensures that the MyPOS maintains a focus on what is 
most important to QOL from the patients’ perspectives. 
 
8.8.   Role of environmental and non-medical factors in QOL 
 
Wilson and Cleary’s model represents ‘Characteristics of the environment’ and ‘Non-medical 
Factors’ as separate domains, each affecting overall QOL in a different way. Non-medical 
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factors are shown by Wilson and Cleary to have an independent influence on overall QOL, 
separate from the rest of the model (Figure 7).  However, the qualitative interviews in the 
present study revealed that non-medical and medical factors were more interconnected in 
the way they affect QOL.  For example, financial concerns (a non-medical factor) were 
reported by one participant as important to QOL, but has arisen as a consequence of back 
pain preventing a patient from earning money (Publication 2, Figure 1).  Of course it is 
conceivable that financial concerns could arise for entirely non-medical reasons, although 
such concerns may still affect health, for example due to an inability to pay for hospital 
parking, or afford a healthy diet.  This interconnectedness of medical and non-medical factors 
has been previously discussed when debating the distinction between QOL and HRQOL.  
Leplage (27) argues that this interconnectedness makes the prospect of specifically 
measuring HRQOL improbable, and notes that this challenge is rarely discussed by those 
working in the field.  Ferrans (75)  also critiques and revises Wilson and Cleary’s model and 
concluded that the ‘Non-medical Factors’ domain should be removed, since all non-medical 
factors could be categorised as properties of either the individual or the environment, both 
of which are included elsewhere in the model.  The model of QOL presented in the present 
study merges Wilsons and Cleary’s ‘characteristics of the environment’ and ‘non-medical 
factors’ into a single ‘support’ domain, to recognise this interconnectedness, and better 
capture the issues raised by participants in the qualitative interviews.  Support factors are 
shown as either ‘heath-service’ or ‘non-health service’ factors, but are all contained with the 
same domain as they interact with other domains and overall QOL in the same way (Figure 8). 
 
Health service factors are within the control of healthcare providers to modify/improve, and 
hopefully therefore to improve QOL.  By contrast, non-health service factors are less easily 
modified by healthcare professionals, since they contain more structural factors (finances, 
housing, transport) or rely on external psychosocial support networks (family, friends, 
employer).  This is reflected in the final MyPOS, which was designed as an aid to clinical care, 
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and so aims primarily to uncover problems that healthcare providers may be able to modify 
or fix, or that may guide treatment.  The MyPOS contains 5 items about healthcare support 
factors, and a single item about financial worries to reflect the non-health service support 
issues.  A MyPOS item about financial worries was included since uncovering financial 
concerns may be useful clinically, for example by triggering referral to a social work team for 
benefits advice. 
 
8.9.   Emotional wellbeing and QOL 
 
Many issues around emotional wellbeing emerged as important to QOL during the qualitative 
interviews.  These are represented in the model as an ‘emotional status’ domain.  In contrast, 
Wilson and Cleary include emotional factors within a broader domain called ‘general health 
perceptions’.  They define general health perceptions as “an integration of [biological, 
physiological, symptom and functional factors], as well as others such as mental health” and 
refer also to psychiatric morbidity within their definition (74).  Wilson and Cleary place 
general health perceptions in a linear relationship with other key domains (symptom status 
 functional status  general health perceptions  overall QOL, see Figure 7).  This would 
imply no direct causal link between symptoms and mental health, unless mediated by a 
change in functional status.  This was not supported by the qualitative data in the present 
study, which suggested that emotional and mental health factors can affect overall QOL in a 
more interconnected way (emotional status  symptom status OR activity and 
participation OR overall QOL).  This is reflected in the revised model by presenting the 
‘emotional status’ domain with direct causal links to multiple other domains, rather than 
within a linear relationship (Publication 2, Figure 3). 
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8.10.   Personal characteristics and QOL 
 
Analysis of the qualitative interviews identified certain personal characteristics that 
influenced QOL in a more complex way.  These were adaptation, coping, expectations, and 
spirituality.  These are shown in an overarching box in the model, representing that they can 
affect how an individual might view the underlying domains, or act as mediators of the causal 
relationships between them (Figure 8).  Examples from the qualitative data to demonstrate 
this are shown in Publication 2, Figure 2. 
 
By contrast, Wilson and Cleary represent personal characteristics as divided between ‘general 
health perceptions’ and ‘characteristics of the individual’ (Figure 3).  They give examples of 
‘characteristics of the individual’ as symptom amplification, motivation, values and 
preferences (Figure 7).  Within their definition of ‘general health perceptions’ they refer to 
other characteristics such as hypochondriacal thinking (74, 123).  They do not describe in 
detail the rational for representing ‘general health perceptions’ and ‘characteristics of the 
individual’ as affecting QOL in different ways.  The model of QOL presented in the present 
study aims to clarify this by separating emotional wellbeing and mental health on the one 
hand, from more fixed personal characteristics on the other (Figure 8). 
 
The finding that personal characteristics such as adaptation, coping, expectations and 
spirituality can act as mediators of QOL echoes the work of Zissi with long-term mental health 
patients (84).  Zissi reports a multiple regression analysis showing that improvements in 
overall QOL were predicted by the strengthening of certain personal characteristics (self-
concept and personal autonomy), but were not predicted by improvements in objective 
indicators (family contacts, leisure time, social relationships, safety, physical health).  They go 
on to develop a mediational model of QOL in which self-concept and personal autonomy 
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mediate the degree to which objective indicators will affect overall QOL.  In a similar way, the 
model developed in the present study contains four meditators (adaptation, coping, 
expectations and spirituality) that can mediate the causal relationships between QOL 
domains (for example, the impact of pain on emotional wellbeing may be mediated by 
spirituality) (Figure 8). 
 
8.11.   Adaptation and expectations in determining QOL 
 
Some participants of the qualitative interviews reported that their physical impairments had 
not impacted on QOL because they had adapted or lowered their expectations (Publication 2, 
Figure 2).  This reflects the work of Calman, who defines QOL as “the difference, at a 
particular moment in time, between the hopes and expectations of the individual and that 
individual’s present experiences” (81).  Calman’s model characterises QOL as the difference 
(or gap) between a person’s expectations and their reality.  When reality exceeds 
expectations QOL will be high; when expectations exceed reality QOL will be low.  In the 
latter case, Calman proposes that QOL might be restored by interventions that either 
improve the reality or help patients to adapt by lowering their expectations.   
 
The role of expectations in determining QOL is reflected in the MyPOS, since some items ask 
the respondent to consider a given problem in the context of their personal preferences or 
expectations.  For example, the items about usual activities, ability to pursuing leisure 
activities and ability to spend time with family and friends all have the best scoring response 
option as ‘Yes, as much as I wanted’.  This takes account of the fact that some respondents 
may have spent no time with family or friends, but may have wanted it this way.  Similarly, 
the MyPOS asks respondents if they have enough information about their illness, treatment 
and the future.  Different individuals will want different levels of information, and some may 
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not want to be fully informed.  This is reflected in the MyPOS response options for these 
items, for which the best scoring option is ‘Enough information, the right amount for me’ 
(Publication 3, Additional File 1: Table S5). 
 
8.12.   The importance of health-service factors in QOL 
 
Every participant in the qualitative interviews identified some aspect of healthcare as being 
important to their QOL.  Specific health-service factors included accessibility, care and 
respect from professionals, competency of professionals, communication and information 
about the illness and treatment, and consistency (Publication 2).  These issues are captured in 
the MyPOS, which contains the 5-item Healthcare support subscale (Publication 3).    
 
The importance of health service factors to people with myeloma has been noted previously 
in other qualitative studies (7, 117, 119, 120), yet these issues are not well captured in most 
existing QOL questionnaires.  The systematic literature review (Publication 1) identified only 3 
existing QOL questionnaires validated in myeloma that contained items about healthcare: the 
EORTC-MY24, the Functional Assessment of Cancer Therapy – Bone Marrow Transplant 
(FACT-BMT), and the Quality of Life Index (QLI) (Publication 1, Table 4).  The FACT-MM is the 
only myeloma-specific QOL tool developed after publication of the systematic review, and 
this also lacks any items about healthcare.   
 
Of the existing QOL tools that do contain healthcare items, the MY24 originally contained 4 
items about satisfaction with doctors’ relationship, care received, information received, and 
feeling listened to.  However, all four of these items were subsequently removed from the 
MY24 following poor psychometric performance and the tool revised to the MY20 (63), with 
the EORTC group no longer recommending the MY24 for use.  The FACT-BMT includes a 
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single item “I have confidence in my nurse(s)” and the QLI includes 2 general items “How 
satisfied are you with you healthcare?” and “How important to you is your healthcare?”  
Neither the FACT-BMT nor the QLI are myeloma-specific tools, and much of their validation 
has taken place in mixed samples (Publication 1, Table 5).  The MyPOS is therefore unique in 
being the only myeloma-specific QOL questionnaire to have a dedicated subscale to capture 
these important issues.   
 
The importance of high quality accessible healthcare to the QOL of myeloma patients may 
have broader implications.   It is known that patients with haematological cancer are more 
likely than patients with other cancers to die in hospital, as opposed to their own home or in 
a hospice (124).  The reasons for this are not fully understood, although it has been suggested 
that the potential for rapid disease progression and blurred transition from curative to 
palliative care may play a role (125).   However, the higher rates of hospital death in 
haematological cancer have been found to persist even with more indolent disease. This 
suggests that the picture is more complex and other factors may be at work (126).  The 
qualitative interviews in the present study highlighted the importance of consistency and 
good relationships with healthcare providers from the perspective of myeloma patients 
(Publication 2).  It is possible that this may be driving patient’s preferences to remain in 
hospital to be cared for by the teams they know and trust.  This hypothesis falls outside the 
scope of the present study, but would be a worthwhile direction for future research. 
 
8.13.   The importance of sex in QOL 
 
Participants of the qualitative interviews reported that sex was important to their QOL, yet 
was often missing from QOL questionnaires (Publication 2).  The importance of sex has also 
been reported in other qualitative work in myeloma (119).  The systematic review revealed 
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six QOL tools with items about sexual function that have been validated for use in myeloma 
patients, although none of these were myeloma-specific questionnaires (Publication 1, Table 
4).  The best validated existing questionnaire identified in the systematic review was the 
EORTC-QLQ-C30 with its myeloma module the MY24 (later the MY20) – which together 
contain no sex item. The FACT-MM questionnaire was developed after the systematic review 
was published, and does contain a single item “I am satisfied with my sex-life” with a five-
point Likert scale from “Not at all” to “Very much” (64). 
 
The findings of the present study suggest that the wording of the FACT-MM sex item may not 
be ideal, since participants of the cognitive interviews found the concept of satisfaction with 
sex to be confusing at times (Publication 3).  Some respondents reported that they could only 
be satisfied with their sex life after having sex, making the question irrelevant if no sexual 
activity had taken place.  The wording of the MyPOS sex item was therefore modified from 
“Have you felt satisfied with your sex life?” to “Have you been worrying about your sex life?”, 
in order to improve comprehension and acceptability to respondents (Publication 3).  This 
resulted in 8.4% of respondents preferring not to answer the item in the cross sectional 
survey (Publication 3).   This is a reasonable response-rate for a question of this kind, with 
others reporting missing responses of 9.9-14.6% for items about sex in older adults (127, 
128).    
 
8.14.   Clinical utility of the MyPOS 
 
The MyPOS was developed using a clinimetric approach, maintaining a focus on clinical utility 
throughout its development.  Examples of where clinimetrics guided the MyPOS 
development include selection of items based on what would be most useful in clinical 
practice; including specific items to uncover clinical problems that often remain hidden (e.g. 
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problems with sex life); retention of items on clinical grounds despite not loading well in the 
factor analysis (e.g. diarrhoea item); retention of items despite skewed distribution of scores 
(e.g. Healthcare Support subscale).  As a result, the MyPOS presents a number of strengths to 
those seeking a questionnaire for clinical use.    
 
The MyPOS healthcare support subscale is unique in myeloma-specific QOL questionnaires.  It 
contains 5 items about being able to contact your doctors or nurses, knowledge and skill of 
doctors and nurses, care and respect from doctors and nurses, information about illness and 
treatment, and information about the future.  Responses to these items can be used to 
highlight and remedy any concerns that individual patients may have about their care, but 
could also be used in aggregate to identify deficiencies in their service provision and make 
improvements where necessary.  
 
The MyPOS sex item (“Over the past week, have you been worrying about your sex life?”)  
captures an important issue that is difficult for both patients and staff to raise in a typical 
clinical encounter.  The inclusion of this item adds important clinical utility in helping to 
uncover hidden problems and facilitate better clinical consultations.  This may help facilitate 
a more detailed discussion, for example by educating patients about the safety of intercourse 
whilst immunocompromised.  It may also prompt referral to other specialist services, such as 
gynaecology or urology for issues such as vaginal dryness or erectile dysfunction after 
chemotherapy. 
 
The MyPOS contains other items that may be useful to other members of a multidisciplinary 
team.  For example “Over the past week have you been worried about your financial 
situation?” may uncover financial concerns that may be remedied by referral to a social 
worker, benefits advisor or charitable organisation.  
 
Chapter 8: Overall discussion and integration 
122 
The layout and scaling of the MyPOS were designed to meet the preferences of patients and 
clinical staff (identified in Publication 2).  It contains a mixture of structured and open 
questions, to ensure the MyPOS is brief and only 2 sides of A4 paper, yet also able to capture 
all possible issues and maintain focus on what is most important to patients.  The best 
existing research tools for use in myeloma (the EORTC-QLQ-C30 and MY20) together take up 
4 sides of A4 and contain no open questions.  By contrast, the MyPOS leads with the question 
“What are your main problems or concerns at the moment?” followed by free text boxes.  
Placing this question first helps ensure that the structured questions do not bias or lead a 
respondent to think in a certain way.  Responses to this question can help clinical staff to 
focus their consultation on what is most important to the patient. 
 
The MyPOS is structured so that items with the same response options are grouped together.  
They are also laid out so that all responses representing worse QOL are toward the right of 
the page, and better QOL to the left.  These were preferences of both patients and staff 
expressed during the qualitative interviews (Publication 2).  Constructing the MyPOS in this 
way means less text to read (and so less burden on respondents), and ensures that 
information on completed paper MyPOS questionnaires can be more easily assimilated by 
clinical staff when interpreting the results in brief clinical encounters. 
 
8.15.   Study limitations and areas for future research 
 
The majority of participants in the qualitative phase of the study were recruited from a single 
centre.  Of 51 participants in the qualitative interviews and focus groups, 45 were recruited 
from King’s College Hospital in inner London (Publication 2).  Arguably this may have 
implications for the QOL issues that emerged, potentially missing issues relevant in district 
general treatment centres or more rural areas.  However, King’s College Hospital is a tertiary 
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centre, providing bone marrow transplant services and follow up for myeloma patients across 
the southeast of England.  As such, not all the participants recruited at the King’s College 
Hospital site were residents of London, some had travelled from surrounding counties for 
treatment or clinic appointments.  The predominance of a single recruitment centre for the 
qualitative work is also balanced by the multi-centre sampling used for the cross sectional 
survey.  The survey recruited from 14 hospital trusts across England, ensuring that the 
psychometric properties of the MyPOS were demonstrated in a sample recruited from across 
the country (Publication 3).   
 
The cross sectional survey used consecutive enrolment, seeking a clinically representative 
sample for the MyPOS validation.  This sampling method is both a strength and a weakness of 
the study.  Consecutive enrolment will not have accessed all available patients, for example 
those who stayed at home due to feeling unwell or those who were approached but declined 
to participate.  An attempt was made to compare the characteristics of the study participants 
with non-participants, but the collection of demographic and treatment data from non-
participants was limited by data protection and ethical considerations, since not all non-
participants were able to give consent for this.  However, the use of consecutive enrolment 
will still have achieved a more clinically representative sample than many other comparable 
studies in multiple myeloma.  It was noted above that much of the validation of existing QOL 
questionnaires in people with myeloma has taken place in highly selected samples alongside 
therapeutic trials of chemotherapy agents (Publication 1).  By contrast, the MyPOS has been 
validated in a sample far more closely matching the population of myeloma patients 
presenting to hospital clinics and wards across the country – since this is the intended target 
group for the MyPOS questionnaire.  One notable consequence of this approach is that only 
4.7% of the MyPOS validation sample were hospital inpatients – a figure that likely reflects 
the proportion of myeloma patients residing in hospital at any given time.  However, further 
validation of the MyPOS specifically in the inpatient setting may be of value in the future. 
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About one quarter of all respondents had help completing the MyPOS questionnaire during 
the validation study, either from a family member or a staff member (Publication 3).  This 
may have introduced bias into the questionnaire responses.  However, this reflects the likely 
reality when using questionnaires of this kind in clinical practice.  The alternative approach 
would have been to exclude participants from the analysis if they needed help completing 
MyPOS, and this would have introduced a significant bias in favour of fitter patients with 
good literacy skills.  Keeping these participants in the analysis again ensured that MYPOS was 
validated in a clinically representative ‘real-world’ sample. 
 
The present study included no longitudinal data collection, and so the responsiveness to 
change and test-retest reliability of the MyPOS could not be assessed.   Important to the 
MyPOS’ clinical utility is its ability to be used with a single individual over a number of 
different time points.  For example to monitor the effect of different treatments on QOL over 
time, and help guide management decisions.  However, the present study does not establish 
the reliability of the MyPOS for this purpose.  The MyPOS must be shown to give the same 
scores at two different time points for individuals whose QOL has not changed (test-retest 
reliability).  In addition, the MyPOS must be shown to have scores that move up and down 
the scale for individuals whose QOL has changed over time (responsiveness) (44).  The 
evaluation of test-retest reliability and responsiveness will require longitudinal data 
collection.  This was not possible within the resources available for the present study, but will 
be the next step in the validation of the MyPOS. 
 
An important consideration when using tools such as the MyPOS in practice is how clinical 
staff should interpret changes in scores over time.  Establishing the smallest MyPOS score 
change that has clinical significance (the minimum important difference) (129) is another 
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important next step in the MyPOS’s validation.  Again, this requires longitudinal data 
collection and so was not possible with the resources available for the present study. 
 
Much of the discussion presented above has related to the MyPOS as an adjunct to clinical 
care, and the importance of good clinical utility.  However, the evaluation of the MyPOS 
within the present study has been limited to its psychometric properties, and has not tested 
its ability to improve patient-level outcomes in clinical practice.  Does the MyPOS uncover 
hidden clinical problems?  Does the MyPOS facilitate better communication?  Does the 
MyPOS improve satisfaction with care?  These would be worthwhile avenues for future 
research. 
 
8.16.   Research implications 
 
The qualitative phase of the MyPOS development employed three different interview 
methods. These were the ‘Issues Interviews’ (semi structured interviews to explore the 
meaning of QOL with open questions), the ‘Questionnaire Interviews’ (semi-structured 
interviews to explore views on existing QOL questionnaires), and focus groups of patients to 
supplement the individual interviews (Publication 2).  The combined use of these methods is 
recommended when developing or refining patient reported outcome measures (130), but 
the contribution of each method to the present findings is worthy of reflection.  The Issues 
Interviews gave rise to the list of QOL issues and were the primary source of data for the 
theoretical model of QOL, which formed the foundation of the MyPOS.  The Questionnaire 
Interviews gave useful data on preferences for layout, formatting and scaling of 
questionnaires, but were limited in their ability to identify important QOL issues and so 
support the content validity of the MyPOS.  The focus groups generated no additional QOL 
issues or preferences for questionnaire design, but supported the findings of the individual 
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interviews and demonstrated that theoretical saturation was achieved independently from 
the interview method used (methodological triangulation, (131)).  
 
A significant portion of each of the Questionnaire Interviews was devoted to exploring the 
importance or relevance of each item to QOL.  Many participants answered in terms of 
whether they had had the problem or not (e.g. “I have never vomited, so that question is not 
relevant to my QOL”), as opposed to considering the potential of each problem to affect QOL 
(“I have never vomited, but if I did then that would affect my QOL”).  Participants of the 
Questionnaire Interviews were also asked to identify missing items or gaps in the existing 
questionnaires.  Most found this question difficult and were unable to give an answer 
(Publication 2).  This is likely to be because such a question is cognitively very complex – the 
question requires the respondent to (i) identify all the issues important to their QOL; (ii) 
retain and recall all the items on a QOL questionnaire; and (iii) compare these two things to 
identify any gaps in the questionnaire.  Even for those few participants who did answer the 
question, it is likely that the responses did not capture the full picture.   In practice, these 
issues made the data from the Questionnaire Interviews difficult to analyse.  It is worth 
remembering that the Questionnaire Interviews were analysed directly from audio, whereas 
the Issues Interviews was analysed following transcription (Publication 2).  This may have 
affected the ease with which meaning could be extracted from the data.  Even so, the 
questions used within the Questionnaire Interviews were based on recommendations for 
studies of this kind (130), yet participants found them difficult to answer.  This raises 
questions in terms of how best to employ qualitative methods to establish the content 
validity of questionnaires:  How should questions be phrased?; Should relevance be explored 
item-by-item or for the measure as a whole?; What is the impact of analysing from audio as 
opposed to following transcription, and should questions be posed in different ways for each 
type of analysis?  These would be useful avenues of enquiry within the field. 
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The discussion presented above describes a number of differences between the MyPOS as a 
clinical tool, and the best existing myeloma questionnaires that were designed as research 
tools.  Developing the MyPOS as a tool specialised for clinical use has required considerable 
resources, but has yielded a tool that is better suited to clinical use than its research 
counterparts.  However, there is evidence that even research tools can confer benefits in 
clinical settings (57). This raises a number of important questions: Are research tools good 
enough for clinical use?; how do specialised clinical tools compare to research tools in terms 
of patient-level outcomes when used in clinical practice?; is the additional resource needed 
to develop and validate separate clinical tools justified?  For example, it may be interesting to 
compare the MyPOS against research tools such as the EORTC-QLQ-C30/MY20, to explore if 
the development of specialised clinical tool carries additional benefit to patients.  These are 
important questions for the field, and worthwhile directions for future research. 
 
8.17.   Clinical implications 
 
The purpose of the tools such as the MyPOS is ultimately to improve the clinical care and QOL 
of people with myeloma.  The findings presented within this thesis go beyond the 
development and validation of the MyPOS questionnaire, but can also inform the best ways 
to provide clinical care to people affected by myeloma. 
 
Firstly, the diverse range of issues identified as important to QOL (Publication 2) re-enforces 
the need for a multidisciplinary approach when caring for myeloma patients.  All of the 
domains in the model of QOL (Figure 8) must be addressed by the treating teams in order to 
maintain good QOL.  In order to optimise QOL patients may therefore require support from 
teams such as specialist palliative care (to optimise the domain of Symptom Status – see 
Figure 8); psychologists and counsellors (Emotional Status); physiotherapists and 
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occupational therapists (Activity and Participation); social workers (Support Factors); and 
spiritual care services.  Note in particular that the domains most closely related to QOL were 
those that may require non-medical support (Emotional Status, Activity and Participation, 
Support Factors).  Within the UK National Health Service most haematology services are 
organised in a way that places a central focus on patients’ medical and nursing needs, with 
patients often expecting only to see their doctor or nurse on a typical clinic visit.   
Haematology doctors and nurses would usually need to access the associated disciplines 
above by separate referral, requiring the patient to return on a different day.  The cross 
sectional survey (Publication 3) showed that many of these problems are active for those 
attending haematology clinics, and so a multidisciplinary clinic model may be more 
appropriate, as opposed to a ‘doctor only’ model.  If all required professionals were present 
in a single clinic, patients could access the help they need on a single visit, to address all their 
problems and concerns.  Completing the MyPOS on arrival to the clinic could identify the 
most pressing problems and concerns for each patient and direct them to the required 
professionals.  MyPOS results could also be used in aggregate to highlight unmet needs and 
build business cases for funding additional services, thereby allowing services to grow and 
evolve in ways that are targeted to the specific needs of the populations they serve. 
 
Secondly, clinical services for people with myeloma should be organised to ensure they 
deliver on those aspects of care that are most important to patients’ QOL.  These were 
identified by patients in the qualitative interviews as accessibility, care and respect, 
communication and information, competency of professionals, and consistency (Publication 2 
and Figure 8).  For example, this might be achieved in practice by providing a 24-hour contact 
telephone number for clinical advice (accessibility), providing access to written information 
about the illness and different treatments (communication and information), and wherever 
possible ensuring that patients see the same doctor each time they attend clinic 
(consistency).  
Chapter 8: Overall discussion and integration 
129 
 
Thirdly, clinical staff must find ways to raise and address difficult or embarrassing issues such 
as sexual function with their patients.  Patients’ worries about their sex life may be related to 
physical issues such as erectile dysfunction or vaginal dryness, or may arise from anxieties 
such as potential infection or bleeding from intercourse during chemotherapy.  Having 
written information or leaflets available on display in the clinic waiting room or online may be 
enough to allay some patient’s concerns and answer their questions.  Making such 
information routine during the chemotherapy consenting process may also help.  Completing 
the MyPOS in the waiting room whilst waiting to see the doctor would be an excellent way to 
give such issues a voice and open up a conservation between patients and staff.  Sometimes 
clinical staff may lack confidence in advising their patients about such issues, and so 
collaboration between haematology, gynaecology and urology teams may be of benefit. 
Educational interventions may help raise awareness within haematology teams of the 
prevalence of sexual dysfunction in their patients, its clinical management, and when referral 
to specialist gynaecological or urological services may be appropriate. 
 
Finally, there are implications for the training of junior doctors.  The principle of using patient 
reported outcomes in routine clinical practice should be included within medical education.  
Currently it is common for students to leave medical school believing that the success or 
failure of cancer treatments depends only on their effect on disease activity – for example by 
measuring the size of a solid tumour on serial CT scans, or in the case of myeloma by 
measuring serial serum paraprotein levels.  It is important for doctors to understand the role 
for monitoring of QOL over time as illness and treatment progress.  This is particularly 
important in the later or palliative stages of illness, where the markers of disease activity may 
continue to deteriorate, yet with good palliative and supportive care QOL may improve.  
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8.18.   Next steps 
 
During the course of carrying out the present study, the study team won additional support 
from another funder to allow the work to be taken further.  A second PhD fellow has been 
appointed to take forward the MyPOS validation.  The MyPOS is currently being tested in a 
longitudinal sample, to evaluate test-retest reliability, responsiveness to change and minimal 
important difference scores for the MyPOS.  Data collection has been completed and analysis 
of these data is underway. 
 
After the longitudinal work has been completed, the next step would be explore the best 
approach to implementing the MyPOS and evaluate its ability to facilitate better care and 
improve outcomes.  As discussed above, the way patient reported outcomes are used in 
practice can affect their ability to confer benefit to patients, and in some circumstances 
implementation without adequate feedback to patients may been harmful (56) (Chapter 1, 
Table 2).  It has also been described how patient reported outcomes might be used at 
different stages in the patient journey, for example on initial presentation, when ordering 
investigations to aid diagnosis, or when formulating treatment plans (132).  Ideally, therefore 
the implementation of the MyPOS into practice would be the subject of a further study to 
explore how it should be used, how information should be fed back to patients and staff, to 
measure the effect of the MyPOS on patient-level outcomes, and importantly to monitor for 
any adverse effects prior to widespread implementation. 
 
It is known that training and education of service users is crucial for successful 
implementation of patient-reported outcomes into clinical practice (133).  After the 
longitudinal and clinical evaluations of the MyPOS have been completed the MyPOS will be 
made available for use via the POS website (www.pos-pal.org).  Annual workshops are run at 
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the Cicely Saunders Institute to provide training for those interested in using the POS family 
of questionnaires in their research or clinical practice.  This training will address many of the 
barriers to implementation outlined above (Chapter 4, Table 4). 
 
The Cicely Saunders Institute hosted a 1 day conference on 31st March 2016 to disseminate 
the MyPOS to service users (Appendix M).  The conference included a presentation of the 
present study and how the MyPOS was developed and validated, a presentation of the 
longitudinal validation, and input from clinical haematologists and myeloma patients.  A 
panel discussion with patients, clinical and research representatives explored the regular 
monitoring of QOL in practice as a prelude to implementation of the MyPOS to improve 
patient care. 
 
8.19.   Conclusion 
 
This study presents the first comprehensive model of QOL from the perspective of people 
with multiple myeloma.  The model provides a robust foundation from which the new MyPOS 
questionnaire was built.  The MyPOS is the first myeloma-specific QOL tool designed 
expressly for clinical use.  It is a brief and acceptable tool that performs well on psychometric 
testing.  Further longitudinal validation is underway, following which the MyPOS will be used 
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17.   Appendix H – Questionnaire booklet 
 
The pages that follow contain a copy of the questionnaire booklet that was given to 
participants of the cross sectional survey during the MyPOS validation.  The booklet contains 
items from a range of questionnaires to allow for validation of the MyPOS items:   
 
 Section A contains items from the MyPOS questionnaire.   
 
 Section B items are reproduced from the EORTC-QLQ-C30 and MY20 questionnaires 
(available at http://groups.eortc.be/qol/).   
 
 Section C items are reproduced from the EQ-5D questionnaire (available at 
http://www.euroqol.org/).  
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